Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
(QTY 18) TREPROSTINIL 0.6MG/ML SOLN,INHL,REFILL KIT - TYVASO 0.6MG/ML REFILL KIT NDC#: 66302-0206-02 is a federal award for 261-Network Contract Office 21 (36C261) held by United Therapeutics Corp. Estimated value $264K ($264K obligated). Current period of performance ends Sep 30, 2024. Last award drew 1 bidder. Place of performance: SILVER SPRING MD. Related solicitation 36C261-24-AP-1328.
(QTY 18) TREPROSTINIL 0.6MG/ML SOLN,INHL,REFILL KIT - TYVASO 0.6MG/ML REFILL KIT NDC#: 66302-0206-02
Recompete timing
PublicCurrent PoP ended Sep 30, 2024 (690 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordUnited Therapeutics Corp — $3.8M obligated across 190 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C26124N0362?
36C26124N0362 (QTY 18) treprostinil 0.6mg ML SOLN) is a 261-Network Contract Office 21 (36C261) award with a potential value of $264K, currently held by United Therapeutics Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C261-24-N-0362?
36C261-24-N-0362 is the dashed form of PIID 36C26124N0362 (QTY 18) treprostinil 0.6mg ML SOLN), held by United Therapeutics Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C26124N0362?
261-Network Contract Office 21 (36C261) awarded 36C26124N0362 to United Therapeutics Corp (potential $264K).
Who is the incumbent on 36C26124N0362?
United Therapeutics Corp is the incumbent with $3.8M across 190 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2024.
When does United Therapeutics Corp’s 36C26124N0362 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 30, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.